Pharm

Ceftaroline

search

Ceftaroline, Ceftaroline Fosamil, Teflaro

  • See Also
  1. Fifth Generation Cephalosporin
  2. Cephalosporin
  • Indications
  1. Bacterial Coverage
    1. Multidrug-resistant Staphylococcus aureus
      1. Methicillin-resistant Staphylococcus aureus (MRSA)
      2. Vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant VISA
      3. Vancomycin-Resistant Staphylococcus aureus)
    2. StreptococcusPneumonia
      1. Includes drug-resistant strains
    3. Respiratory Gram-Negative Bacteria (including Beta-Lactamase-positive Bacteria)
      1. Moraxella catarrhalis
      2. HaemophilusInfluenzae
  2. Conditions
    1. Community Acquired Pneumonia
    2. Skin and Soft Tissue Infection
  • Mechanism
  1. Ceftaroline Fosamil is infused and hydrolyzed to the active form, Ceftaroline
  2. Inactivates Penicillin-binding Proteins on the inner membrane of the Bacterial cell wall (similar to other beta lactams)
    1. Interferes with cross-linkage of peptidoglycan chains, reducing Bacterial cell wall strength and rigidity
  • Dosing
  • Adult
  1. Standard Dosing
    1. Give 600 mg IV every 12 hours infused over 5 to 60 minutes
  2. Renal Dosing
    1. eGFR 31 to 50 ml/min: 400 mg IV every 12 hours
    2. eGFR 15 to 30 ml/min: 300 mg IV every 12 hours
    3. eGFR <15 or Hemodialysis: 200 mg IV every 12 hours
  • Dosing
  • Child
  1. Age 2 months to 2 years
    1. Give 8 mg/kg IV every 12 hours
  2. Age >2 years and weight <33 kg
    1. Give 12 mg/kg IV every 8 hours
  3. Age >2 years and weight >33 kg (Adult dosing)
    1. Give 400 mg IV every 8 hours OR
    2. Give 600 mg IV every 12 hours
  • Pharmacokinetics
  1. Ceftaroline Fosamil is hydrolyzed to the active form, Ceftaroline in vivo
  2. Elimination Half-Life: 3 hours
  • Adverse Effects
  1. Hemolytic Anemia (rare)
  • Safety
  1. Pregnancy Category B
  2. Considered safe in Lactation
  • Resources
  1. Ceftaroline (DailyMed)
    1. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3ecde48b-75a2-4beb-9999-369f3f61bb8a
  • References
  1. Steed (2010) Pharmacotherapy 30(4):375-89 +PMID: 20334458